Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Interest & Investment Income (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Interest & Investment Income for 15 consecutive years, with $10.8 million as the latest value for Q1 2026.

  • For Q1 2026, Interest & Investment Income fell 32.9% year-over-year to $10.8 million; the TTM value through Mar 2026 reached $51.1 million, down 7.59%, while the annual FY2025 figure was $56.4 million, 17.25% up from the prior year.
  • Interest & Investment Income hit $10.8 million in Q1 2026 for Agios Pharmaceuticals, down from $12.4 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $18.0 million in Q4 2024 and bottomed at $694000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $9.5 million, with a median of $8.6 million recorded in 2023.
  • Year-over-year, Interest & Investment Income soared 2048.91% in 2022 and then crashed 32.9% in 2026.
  • Agios Pharmaceuticals' Interest & Investment Income stood at $6.5 million in 2022, then soared by 32.92% to $8.6 million in 2023, then soared by 108.89% to $18.0 million in 2024, then plummeted by 31.11% to $12.4 million in 2025, then decreased by 13.01% to $10.8 million in 2026.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $10.8 million, $12.4 million, and $13.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.